- Home
- CHN vs SAVA Comparison
CHN vs SAVA Comparison
Compare CHN & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHN
- SAVA
- Stock Information
- Founded
- CHN 1992
- SAVA 1998
- Country
- CHN United States
- SAVA United States
- Employees
- CHN N/A
- SAVA N/A
- Industry
- CHN Investment Managers
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- CHN Finance
- SAVA Health Care
- Exchange
- CHN Nasdaq
- SAVA Nasdaq
- Market Cap
- CHN 128.4M
- SAVA 137.2M
- IPO Year
- CHN N/A
- SAVA N/A
- Fundamental
- Price
- CHN $11.51
- SAVA $1.44
- Analyst Decision
- CHN
- SAVA Buy
- Analyst Count
- CHN 0
- SAVA 3
- Target Price
- CHN N/A
- SAVA $54.50
- AVG Volume (30 Days)
- CHN 31.8K
- SAVA 2.2M
- Earning Date
- CHN 01-01-0001
- SAVA 05-09-2025
- Dividend Yield
- CHN 0.19%
- SAVA N/A
- EPS Growth
- CHN N/A
- SAVA N/A
- EPS
- CHN N/A
- SAVA N/A
- Revenue
- CHN N/A
- SAVA N/A
- Revenue This Year
- CHN N/A
- SAVA N/A
- Revenue Next Year
- CHN N/A
- SAVA N/A
- P/E Ratio
- CHN N/A
- SAVA N/A
- Revenue Growth
- CHN N/A
- SAVA N/A
- 52 Week Low
- CHN $9.00
- SAVA $1.15
- 52 Week High
- CHN $12.98
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- CHN 38.88
- SAVA 37.19
- Support Level
- CHN $11.40
- SAVA $1.17
- Resistance Level
- CHN $11.95
- SAVA $1.46
- Average True Range (ATR)
- CHN 0.35
- SAVA 0.13
- MACD
- CHN -0.05
- SAVA 0.04
- Stochastic Oscillator
- CHN 39.91
- SAVA 60.42
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.